CF
Cantor Fitzgerald Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
|
RDHL
501
Redhill Biopharma
RDHL
$3.31M
|
BF
Brandon Folkes
| $1.42 | $22,000 |
1,549,196%
upside
| Overweight |
31 Aug ‘21
4 years ago |
|
502
Rani Therapeutics
RANI
$23.9M
|
BF
Brandon Folkes
| $0.4994 | $23 |
4,506%
upside
| Overweight |
24 Aug ‘21
4 years ago |
|
|
ATON
503
AlphaTON Capital Corp. Common Stock
ATON
$13.4M
| $6 | $700 |
11,567%
upside
| Overweight |
19 Aug ‘21
4 years ago |
|
|
504
Arcturus Therapeutics
ARCT
$484M
|
BC
Brian Cheng
| $17.94 | $85 |
374%
upside
| Overweight |
10 Aug ‘21
4 years ago |
|
505
Collegium Pharmaceutical
COLL
$1.19B
|
BF
Brandon Folkes
| $37.97 | $22 |
42%
downside
| Neutral |
6 Aug ‘21
4 years ago |
|
506
BioCryst Pharmaceuticals
BCRX
$1.72B
|
BC
Brian Cheng
| $8.08 | $21 |
160%
upside
| Overweight |
3 Aug ‘21
4 years ago |
|
507
PolyPid
PYPD
$55M
|
BF
Brandon Folkes
| $3.49 | $720 |
20,530%
upside
| Overweight |
30 Jul ‘21
4 years ago |
|
508
Adverum Biotechnologies
ADVM
$74.3M
|
AY
Alethia Young
| $3.47 | $30 |
765%
upside
| Neutral |
23 Jul ‘21
4 years ago |
|
509
Jaguar Health
JAGX
$4.31M
|
LC
Louise Chen
| $1.93 | $1,687,500 |
87,435,133%
upside
| Overweight |
7 Jul ‘21
4 years ago |
|
510
Hyliion Holdings
HYLN
$289M
|
JC
Josh Cohen
| $1.61 | $17 |
956%
upside
| Overweight |
6 Jul ‘21
4 years ago |
|
511
Dianthus Therapeutics
DNTH
$1.02B
|
EN
Emma Nealon
| $35.57 | $320 |
800%
upside
| Overweight |
29 Jun ‘21
4 years ago |
|
512
cbdMD
YCBD
$6.31M
|
PZ
Pablo Zuanic
| $0.7168 | $1,170 |
163,125%
upside
| Neutral |
18 Jun ‘21
4 years ago |
|
513
ADC Therapeutics
ADCT
$396M
|
BC
Brian Cheng
| $3.32 | $46 |
1,286%
upside
| Overweight |
15 Jun ‘21
4 years ago |
|
514
RAPT Therapeutics
RAPT
$220M
|
AY
Alethia Young
| $13.60 | $568 |
4,076%
upside
| Overweight |
14 Jun ‘21
4 years ago |
|
515
Vertex Pharmaceuticals
VRTX
$101B
|
AY
Alethia Young
| $396.48 | $281 |
29%
downside
| Overweight |
11 Jun ‘21
4 years ago |
|
516
CareCloud
CCLD
$144M
|
SH
Steven Halper
| $3.56 | $15 |
321%
upside
| Overweight |
11 Jun ‘21
4 years ago |
|
517
HealthEquity
HQY
$8.02B
|
SH
Steven Halper
| $92.99 | $85 |
9%
downside
| Overweight |
8 Jun ‘21
4 years ago |
|
518
Avalo Therapeutics
AVTX
$150M
|
LC
Louise Chen
| $11.61 | $7 |
40%
downside
| Overweight |
4 Jun ‘21
4 years ago |
|
|
CMMB
519
Chemomab Therapeutics
CMMB
$15.8M
|
KK
Kristen Kluska
| $3.05 | $180 |
5,802%
upside
| Overweight |
26 May ‘21
4 years ago |
|
520
Ocugen
OCGN
$322M
|
KK
Kristen Kluska
| $1.03 | $11 |
968%
upside
| Neutral |
7 May ‘21
4 years ago |
|
521
89bio
ETNB
$1.27B
|
EN
Emma Nealon
| $8.63 | $58 |
572%
upside
| Overweight |
21 Apr ‘21
4 years ago |
|
522
Ovid Therapeutics
OVID
$88.2M
|
CD
Charles Duncan
| $1.24 | $4 |
223%
upside
| Neutral |
20 Apr ‘21
4 years ago |
|
523
PAVmed
PAVM
$9.41M
|
KM
Kyle Mikson
| $0.4300 | $49.20 |
11,342%
upside
| Overweight |
30 Mar ‘21
4 years ago |
|
524
Marker Therapeutics
MRKR
$11.3M
|
KK
Kristen Kluska
| $0.8510 | $60 |
6,951%
upside
| Overweight |
19 Mar ‘21
4 years ago |
|
525
Akebia Therapeutics
AKBA
$830M
|
AY
Alethia Young
| $3 | $8 |
167%
upside
| Overweight |
8 Mar ‘21
4 years ago |
|